Clinical Trial

Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)

Study acronym: GEMA-proN
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
GEMA-proN is an observational, multicenter, single cohort, retrospective clinical trial. The aim of the trial is to assess the prevalence, and prognostic value of genetic molecular alterations and investigate correlations with clinicopathological features in unselected patients with histologically confirmed non-small cell lung cancer (NSCLC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-10.
Trial Details
NCT Number NCT06876402
Lead Sponsor Hellenic Cooperative Oncology Group
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 367 participants
Start Date 2013-09-09
Primary Completion 2024-10-13 (estimated)
Study Completion 2025-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-05-23